Role of intralesional antigen immunotherapy in the treatment of warts

Correspondingauthor:Najat Hossain Saed Email:Najat91hossain@gmail.com Abstract Background:Warts are the most common clinical manifestation of human papillomavirus (HPV) infection in the skin and mucous membranes, mostly found on the hands, feet, face, and genitalia. These benign lesions have different clinical forms. There are over 200 types of this virus and some of them have contributed in the pathophysiology of wart. Each of its types is different in at least 10% of the sequences encoded by major capsid gene (L1). Although these viruses have a tendency to infect some specific body parts, this disease may be manifested in approximately all regions of the skin and mucosa. In some previous studies, it has been shown that mumps-measles-rubella (MMR) vaccine results in regression of warts via immunomodulation and induction of delayed (cellular) hypersensitivity reactions at the wart tissue. This method can be used in larger populations because of vaccine availability and safety. The varicella zoster (VZV) vaccine, which contains live attenuated virus derived from the OKA strain.